Empagliflozin, metformin and insulin degludec, during pregnancy: a case report
The DOI matches its Crossref record; the references it cites are not checked yet.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Human data was identified in the form of a case report on SGLT2 inhibitor use during pregnancy of a 31-year-old woman with type 2 diabetes on empagliflozin, metformin and insulin degludec who was found to be pregnant at the 5th week of gestation (45). After pregnancy confirmation, empagliflozin was discontinued immediately and metformin was discontinued after the first trimester. She gave birth to”
From Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence (2023) · cites this paper as [45]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 4 · Cited by 18
Metadata
- Authors
- Formoso, G., Ginestra, F., Di Dalmazi, G., & Consoli, A.
- Affiliations
- University of Chieti-Pescara (IT)
- Corresponding author
- Formoso, G.
- Venue
- Acta Diabetologica
- Published
- 2018-03-29
- Volume
- 55
- Issue
- 7
- Pages
- 759-761
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2795368662
- Cited by
- 18
- References
- 4
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 3
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- empagliflozin, metformin, insulin degludec, pregnancy, type 2 diabetes in pregnancy, SGLT2 inhibitors, insulin therapy, drug safety in pregnancy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Empagliflozin, metformin and insulin degludec, during pregnancy: a case report. https://app.cochat.ai/papers/10.1007/s00592-018-1134-y
- The paper
- Formoso, G., Ginestra, F., Di Dalmazi, G., & Consoli, A. (2018). Empagliflozin, metformin and insulin degludec, during pregnancy: a case report. Acta Diabetologica. https://doi.org/10.1007/s00592-018-1134-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.